Drug Company Gains Access to 23andMe's Massive DNA Library
Credit:
Next Gov
Major pharmaceutical company GlaxoSmithKline has inked a four year deal with 23andMe, a genetic testing company that has a massive database of DNA information.
The partnership, announced Wednesday, will focus on the development of new drug treatments, beginning with a focus on possible treatments for Parkinson's disease.
Roughly 5 million people have submitted a DNA sample to 23andMe to discover their ancestral background as well as general information about their health, such as certain conditions and diseases they might be predisposed to. Customers won't be required to participate in the $300 million deal, however.
